According to Millennium Research Group’s (MRG’s) European Markets for Urological Devices 2009 report, the prostate cancer device market-comprising brachytherapy seeds, cryotherapy, and high-intensity focused ultrasound (HIFU) devices-will be driven by earlier detection of prostate cancer due to an increase in screening over the next five years. Screening allows for early detection of cancer, enabling treatment at a curable stage that can be facilitated through minimally invasive devices, such as those required for brachytherapy, cryotherapy, and HIFU procedures.